RxDoctor Payments Data

Susan Liang

Glaucoma Specialist · Taunton, MANPI 1235125980

Payments from drug & device makers

What this record shows

11 manufacturers reported payments, led by Beaver-visitec International, Inc. at 49.7% of the total. Reporting peaked in 2024 at $1,354 and has fallen 69.0% since, to $420 in 2025.

$2,614in general payments, 2019–2025

Across 28 payments — averaging $93.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beaver-visitec International, Inc.$1K
  • AbbVie$765
  • Sun Pharmaceutical Industries Inc.$114
  • Rxsight Inc$111
  • Nova Eye, Inc.$93
  • Oyster Point Pharma, Inc.$89
  • plus $143 from 5 others

What the payments were for

  • Consulting fees$1,29950%
  • Food & beverage$1,31550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$384,110
Medicare patients
973
Services billed
3,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost127$79,189
RestasisCyclosporine65$77,601
RhopressaNetarsudil Mesylate58$32,059
Alphagan PBrimonidine Tartrate59$30,408
ZioptanTafluprost/Pf54$29,518
Latanoprost1,767$26,902
Dorzolamide-TimololDorzolamide/Timolol/Pf107$25,008
Brimonidine Tartrate391$23,661
CombiganBrimonidine Tartrate/Timolol49$22,764
TafluprostTafluprost/Pf81$19,985
Prednisolone Acetate417$18,429
RocklatanNetarsudil Mesylat/Latanoprost19$17,429
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat599$12,001
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$11,831
Travoprost56$10,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$765$209,961300 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$40$49,48877 claims
AlconAzopt, Simbrinza$58$7,87123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Massachusettson file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Taunton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →